Stockreport
Blueprint Medicines inks deal with CStone Pharmaceuticals to develop and commercialize Avapritinib, BLU-554 and BLU-667 in China [Seeking Alpha]
Last blueprint medicines corp earnings: 10/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF
Blueprint Medicines inks deal with CStone Pharmaceuticals to develop and commercialize Avapritinib, BLU-554 and BLU-667 in ChinaBlueprint Medicines (NASDAQ:BPMC) and CStone Pharmaceuticals, a privately-held biopharmaceutical companyannounces an exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies.Avapritinib, BLU-554 and BLU-667 are potent and highly selective investigational kinase medicines that have each demonstrated clinical proof-of-concept in genomically defined subsets of patients with cancer. Blueprint Medicines will retain all rights to the licensed products in the rest of the world.Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $40M and up to ~$346M in milestones. In addition, CStone Pharmaceuticals will be obligated to pay Blueprint Medicines tiered percentage ro
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BPMC | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BPMC alerts
BPMC alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corp news events
Weekly update
A roundup of the hottest topics
BPMC
NEWS
NEWS
- Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis[PR Newswire]
- Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.[MarketBeat]
- Cancer Research Highlight: Blueprint Medicines Lets Loose In GIST [Seeking Alpha][Seeking Alpha]
- Blueprint Medicines Corp (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Cowen Inc.[MarketBeat]
- Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy[PR Newswire]
- More
BPMC
SEC Filings
SEC Filings
- 12/3/18 - Form 8-K
- 11/21/18 - Form 4
- 11/15/18 - Form 8-K
- BPMC's page on the SEC website
- More